The present standard of care (SOC) for patients infected with HCV genotype 1, the most prevalent global genotype, is pegylated interferon (PEG IFN) combined with ribavirin (RBV) for 48 weeks.[4] However, sustained virological response (SVR), defined as the reduction of serum HCV RNA to undetectable levels 24 weeks after the completion

of therapy, is achieved in only 42–52% of patients.[5-7] Moreover, response rates are influenced by patient factors such as sex, age and ethnicity,[8-10] as well as virological factors such as genotype and viral load.[11] SVR rates remain unsatisfactorily low (22%) in women aged 50 years or more who are infected with HCV genotype 1 in Japan.[12] Hence, there is a pressing need to improve the efficacy of antiviral treatment in such patients. Recently, a new class of drugs, with a mechanism based on inhibition of the NS3/NS4 protease of the HCV polyprotein,

Selleckchem Pexidartinib has been investigated for the treatment of chronic hepatitis C. Of the drugs in this class, telaprevir www.selleckchem.com/small-molecule-compound-libraries.html has been selected as a clinical candidate for further development.[13] Telaprevir combined with PEG IFN and RBV has shown potent antiviral activity in phase II[14, 15] and III clinical trials;[16, 17] SVR rates of approximately 70% have been reported in patients infected with HCV-1. Similarly, in Japan, a phase III study was conducted in patients with HCV-1 to compare the efficacy and safety of the telaprevir regimen with those of the current SOC in treatment-naïve patients,[18] and to assess

the efficacy and safety of the telaprevir regimen in relapsers medchemexpress and non-responders after previous IFN-based therapy.[19] However, the high efficacy was offset by treatment-induced anemia: early hemoglobin levels during triple therapy decreased by up to 4 g/dL, whereas decreases with SOC were not higher than 3.0 g/dL.[14, 15] Additionally, we have previously reported that the factors associated with decreases in hemoglobin levels during triple therapy included female sex and age of more than 50 years.[20] Japanese patients infected with HCV genotype 1b with high viral loads are, on average, much older than Western patients infected with the same genotype, owing to a widespread HCV infection that occurred in Japan approximately 20 years ago.[21] Therefore, we considered that triple therapy would be highly effective when combined with careful monitoring of hemoglobin levels and prompt modification of RBV dose. Consequently, in this study, we evaluated the effectiveness and safety of telaprevir-based triple therapy, administrated at an initial telaprevir dose of 2250 or 1500 mg/day, in the retrospective matched control study of 120 Japanese patients with chronic HCV-1 infection with high viral loads.